The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN...

This year, the Food and Drug Administration (FDA) made history — for all the wrong reasons.

FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640

Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Updated: Sep 1, 2019

I’m disappointed and you should be too. Today, the Food & Drug Administration announced the approval of flibanserin, a proposed treatment for “hypoactive sexual desire disorder” in women. Since its founding, the National Women’s Health Network has ensured that the...

FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640

Learn about 5 common myths surrounding sex drugs like Addyi and Viagra as well as the FDA’s approach to this issue. Updated: Oct 6, 2018

For the first time ever, a committee of scientific advisors has recommended the FDA approve a libido drug for women. “Female Viagra” could be on pharmacy shelves by early next year if the FDA follows that recommendation.

FOR IMMEDIATE RELEASE  Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788

Over the last five years the National Women’s Health Network has, on numerous occasions, weighed in on the Food and Drug Administration’s (FDA) review of flibanserin, a drug intended to treat female sexual dysfunction.